Biotech, Food, Drug

The food we eat and the medicine we put into our bodies are highly regulated by a variety of government agencies. In the United States by the Food and Drug Administration (FDA) and the United States Department of Agriculture (USDA) regulate the processes by which food makes its way to the grocery store and medicine is approved for consumer use.  As the science grows more complex behind the pharmaceutical and food industry, interpretation of the regulations in place is becoming more nuanced.  Overseas, these industries are regulated by a variety of agencies; for example, the Minister of Agriculture in Canada, Centre for Food Safety in Hong Kong, and the Committee of Environmental, Public Health and Food Safety (EU), are among the many governing-bodies which regulate biotechnology, food, and drugs throughout the world.

The National Law Review is your free online resource to agency news, emerging topics in food and drug, and the latest in biotechnology updates. From nanotechnologies being used in research, to regulations of imported foods coming into the US from overseas or the development of medical devices and drugs, readers can find expert legal analysis of the developments in the industry, as well as reports on changes within the agencies that regulate these industries. The National Law Review also covers topics related to licensing, Food Safety and Inspection Services (FSIS), food and beverage regulation in the US and worldwide, nutrition labeling, and country of origin labeling guidelines.

With recent legislation being passed throughout the US in relation to marijuana use, both for recreational and medicinal purposes, readers will also find up-to-date information, litigation, and news coming from this area of interest as well. Regulations in California for labeling and proper sales of marijuana, to use in different states, or internationally, as well as rules for promoting and advertising marijuana are also covered on the site. Additionally, the development and changing landscape of tobacco use to include vaping, and how e-cigarettes and vaping are regulated, is also covered by NLR authors.

Readers who are interested in food safety, inspection, imports into the US, and regulations, these topics are covered regularly on The National Law Review as well. New legislation from the FDA, USDA, Department of Agriculture, and international bodies, are covered on the site. If you are looking for details on new nutrition-labeling regulations or health risks of consuming certain imported foods, you will find these topics, and many more, on The National Law Review.

For hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis Twitter feed, and sign up for complimentary e-news bulletins.

Custom text Title Organization Sort descending
Jan
13
2011
New Defense Authorization Act Imposes Buy American Act Mandate for Photovoltaics Sheppard, Mullin, Richter & Hampton LLP
Nov
2
2018
OIG Report on Topical Compounded Drug Prescribing, Marketing and Billing Practices Signals Heightened Administrative and Enforcement Scrutiny Sheppard, Mullin, Richter & Hampton LLP
Mar
2
2019
The Farm Bill’s Impact on Hemp and CBD – and How Some States are Reacting Sheppard, Mullin, Richter & Hampton LLP
May
11
2022
Warning! FDA Issues Warning Letters for Products Containing Delta-8 THC Sheppard, Mullin, Richter & Hampton LLP
Jun
27
2022
Supreme Court Rules for Physicians in Blow to DOJ Sheppard, Mullin, Richter & Hampton LLP
Dec
16
2014
Sandoz and Celltrion Decline the Invitation to Dance: Biosimilars Challenge the Applicability of the BPCIA’s Exchange Provisions Before Bringing Suit Sheppard, Mullin, Richter & Hampton LLP
Jul
21
2022
FDA Issues Final Guidance on Drug and Biological Instructions for Use (IFU) Sheppard, Mullin, Richter & Hampton LLP
Feb
19
2015
Go For De Novo: FDA’s Revised Approach to Medical Device Accessories Sheppard, Mullin, Richter & Hampton LLP
Oct
13
2022
OIG Limits Pharmaceutical Manufacturers’ Ability to Offer Drug Cost-Sharing Subsidies Sheppard, Mullin, Richter & Hampton LLP
Sep
30
2019
CBD Industry Beware: The False Labeling Class Action Has Arrived Sheppard, Mullin, Richter & Hampton LLP
Oct
3
2019
Third Circuit Holds that SLUSA Does Not Preclude Class Action Opt-Outs from Pursuing Individual Actions Sheppard, Mullin, Richter & Hampton LLP
Oct
30
2019
BREAKING NEWS: USDA Releases Interim Final Hemp Rule Sheppard, Mullin, Richter & Hampton LLP
Mar
29
2023
FDA Issues First Untitled Letter of the Year to HCT/P Manufacturer Sheppard, Mullin, Richter & Hampton LLP
Mar
5
2020
How FDA is Reacting to the Coronavirus, and 2020 Regulatory Priorities Sheppard, Mullin, Richter & Hampton LLP
Mar
11
2020
FDA Commissioner Signals Enforcement Policy, Advancement of Research for CBD Products Sheppard, Mullin, Richter & Hampton LLP
Oct
17
2023
United Cannabis Corporation v. Pure Hemp Collective Inc. Sheppard, Mullin, Richter & Hampton LLP
May
11
2020
The Expansion of Cardiovascular Procedures in the ASC Setting Sheppard, Mullin, Richter & Hampton LLP
Oct
25
2023
Connecticut Follows in the Footsteps of Other Jurisdictions Requiring Registration of Pharmaceutical Representatives Sheppard, Mullin, Richter & Hampton LLP
Jul
13
2020
FDA Announces Plans to Resume Domestic On-site Inspections Sheppard, Mullin, Richter & Hampton LLP
Jun
23
2013
Federal Trade Commission (FTC) v. Actavis: What Does It Mean for Reverse-Payment Settlements? Sheppard, Mullin, Richter & Hampton LLP
Jul
4
2013
European Union (EU) Carbon Trading System Wins Parliament's Support Sheppard, Mullin, Richter & Hampton LLP
Jun
26
2018
Ninth Circuit Confirms that Class Action Plaintiffs Must Plausibly Establish Future Intent To Re-Purchase To Maintain Claims for Injunctive Relief Sheppard, Mullin, Richter & Hampton LLP
Sep
28
2021
Nota Bene Episode 145: Tuna Sustainability: A Model Bigger than its Niche with ISSF President Susan Jackson [PODCAST] Sheppard, Mullin, Richter & Hampton LLP
Oct
18
2021
California Broadens Security and Breach Laws, Includes Genetic Data Sheppard, Mullin, Richter & Hampton LLP
Jan
4
2022
Cannabis Legislation Year-in-Review Sheppard, Mullin, Richter & Hampton LLP
Feb
11
2022
Federal Cannabis Reform – Is 2022 the Year? Sheppard, Mullin, Richter & Hampton LLP
Apr
4
2022
The House Does It Again: MORE Act Ready for Senate Action Sheppard, Mullin, Richter & Hampton LLP
Jun
13
2022
States Target Infant Formula Price Gouging Sheppard, Mullin, Richter & Hampton LLP
May
8
2019
AAFCO Issues Updated Guidelines Regarding Hemp in Animal Food Sheppard, Mullin, Richter & Hampton LLP
Jun
27
2022
PFAS Regulations Could Open Floodgates to Prop 65 Enforcement – Assess & Manage Your Exposure Now Sheppard, Mullin, Richter & Hampton LLP
May
20
2019
Location Matters – Manufacturing Insights from FDA’s Annual Report on Drug Quality Sheppard, Mullin, Richter & Hampton LLP
Dec
10
2019
FDA Issues Warning Letters to 15 Companies, Consumer Update on CBD Safety Sheppard, Mullin, Richter & Hampton LLP
Apr
15
2020
FCPA Landmines Beneath the Surface of the COVID-19 Crisis - May 6 Sheppard, Mullin, Richter & Hampton LLP
May
5
2020
IP Protection and the Open COVID Cure Chase Sheppard, Mullin, Richter & Hampton LLP
Dec
13
2023
Federal Circuit Evaluates Impact of the Final Written Decision (FWD) in a Parallel Inter-Partes Review (IPR) on District Court’s decision of Invalidity and Infringement Sheppard, Mullin, Richter & Hampton LLP
Jan
18
2024
Federal Circuit Affirms Skinny Label Carve Outs Sheppard, Mullin, Richter & Hampton LLP
Feb
29
2024
District Court Elucidates the Meaning of “to Induce” Under the Federal Health Care Program Anti-Kickback Statute Sheppard, Mullin, Richter & Hampton LLP
Oct
20
2020
California Governor Pulls the Plug on Genetic Information Privacy Act Sheppard, Mullin, Richter & Hampton LLP
Mar
29
2021
FDA Announces First Ever Facility Fees for OTC Drug Manufacturers Sheppard, Mullin, Richter & Hampton LLP
Apr
15
2021
Breaking Down FDA’s New Remote Monitoring Strategy Sheppard, Mullin, Richter & Hampton LLP
Nov
16
2010
Proposition 23's Failure Means Full Speed Ahead on AB 32 Sheppard, Mullin, Richter & Hampton LLP
Feb
9
2018
Temporal Proximity Is Not Enough: Third Circuit Nixes FCA/Anti-Kickback Suit For Failure To Link Alleged Scheme to Claims Sheppard, Mullin, Richter & Hampton LLP
Jul
2
2021
340B Drug Pricing Discount Program Update: HRSA Now Demands That Drug Manufacturers Provide 340B Discounts To Contract Pharmacies Amid Ongoing Litigation Sheppard, Mullin, Richter & Hampton LLP
Jul
30
2013
Food and Drug Administration (“FDA”) Draft Guidance For Industry On Pre-Launch Activities Importation Requests: Dead On Arrival? Sheppard, Mullin, Richter & Hampton LLP
Aug
9
2013
Unusual Circumstances: California Supreme Court Upholds Limited Use of Future Conditions Baseline Under California Environmental Quality Act (CEQA) Sheppard, Mullin, Richter & Hampton LLP
Sep
29
2021
Impact of NYC’s New Delivery Service Data Sharing Requirement Sheppard, Mullin, Richter & Hampton LLP
Feb
14
2019
HIMMS19 Conference – Blockchain Symposium Recap Sheppard, Mullin, Richter & Hampton LLP
Apr
18
2022
China Proposed Draft Implementing Rules for Human Genetic Resources Management Sheppard, Mullin, Richter & Hampton LLP
May
19
2022
FDA White Paper Signals Shift to Performance-Based Reviews of Mature Quality Systems Sheppard, Mullin, Richter & Hampton LLP
May
1
2019
Yes, UCANN! Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins